Immuron Acquires Oral Immunotherapy IP from Hadasit in Exchange for Equity | GenomeWeb

Australian biopharmaceutical company Immuron has acquired intellectual property related to oral immunotherapies from Hadasit, the technology-transfer arm of Hadassah University Medical Center in Israel, the organizations said this week.

The deal establishes Hadasit as the largest shareholder in Immuron with a 19.99 percent stake, Hadasit and Immuron said.

The IP relates to the concept of treating automimmune and chronic disease with orally delivered polyclonal antibodies, developed by Yaron Ilan and colleagues at Hadassah.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.